This page connects to the broader neurodegenerative disease knowledge graph:
- Diseases: [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), ALS, FTD, [Huntington's disease](/diseases/huntingtons-disease), PSP, MSA
- Brain regions: [substantia nigra](/brain-regions/substantia-nigra), striatum, motor cortex, hippocampus, frontal cortex
- Cell types: [dopaminergic neurons](/cell-types/mesencephalic-dopaminergic-neurons), [astrocytes](/cell-types/astrocytes), [microglia](/cell-types/microglia), motor neurons, oligodendrocytes
- Proteins/Genes: tau, [alpha-synuclein](/proteins/alpha-synuclein), TDP-43, SNCA, GBA, LRRK2, C9orf72, HTT
- Mechanisms: [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), [lysosomal dysfunction](/mechanisms/lysosomal-dysfunction), [protein aggregation](/mechanisms/protein-aggregation), [oxidative stress](/mechanisms/oxidative-stress), [autophagy](/mechanisms/autophagy), [synaptic dysfunction dysfunction](/mechanisms/synaptic dysfunction-dysfunction)
- Therapeutics: [gene therapy](/therapeutics/gene-therapy-neurodegeneration), ASOs, CRISPR gene editing, deep brain stimulation
- Pathways: complement system, neurotrophic signaling, cell death pathways
This therapeutic concept leverages advances in AAV capsid engineering to achieve enhanced brain delivery for gene therapy approaches targeting neurodegenerative diseases. While traditional AAV serotypes (AAV2, AAV9, AAVrh.10) provide some CNS transduction, engineering novel capsids can dramatically improve blood-brain barrier (BBB) crossing, cell-type specificity, and reduce immunogenicity—addressing the primary bottleneck in CNS gene therapy.
The blood-brain barrier remains the primary obstacle for CNS gene therapy. Standard AAV serotypes require high doses for meaningful brain transduction, increasing manufacturing costs and immunogenicity risks. Engineered capsids offer a solution by:
- Enhanced BBB transcytosis — Modified capsids can bind to specific BBB receptors (e.g., LDLR, transferrin receptor) enabling receptor-mediated transcytosis
- Cell-type specificity — Directed evolution selects for capsids that preferentially transduce neurons, astrocytes, or microglia
- Immune evasion — Capsid modification can reduce pre-existing neutralizing antibody recognition
- Lower dosing requirements — Enhanced brain delivery reduces required vector genomes, improving safety
Different neurodegenerative diseases require distinct cell-type targeting:
- Rational design — Insertion of targeting peptides (e.g., transferrin receptor-binding peptides) into capsid surface loops
- Directed evolution — Multiple rounds of selection using in vivo BBB models to identify variants with enhanced brain transduction
- Machine learning-guided design — Computational prediction of capsid variants with optimized properties
- AIMD (Abolish Immune-Mediated Degradation) — Mutations reducing immunogenicity while preserving transduction
| Capsid |
Properties |
Relevance |
| AAV-PHP.B |
Enhanced CNS transduction via unknown mechanism |
Broad neurodegeneration |
| AAV-PHP.EB |
Even higher CNS transduction, reduced peripheral toxicity |
Pre-clinical |
| AAV-CAP-NN |
Machine learning-designed, BBB-crossing |
Development |
| AAV-9 null |
Reduced liver tropism, enhanced CNS |
Clinical |
Engineered capsids can be combined with RNA-targeting payloads:
- ASO delivery — Direct brain injection with engineered AAV capsids for sustained ASO expression
- ** RNAi/SiRNA** — AAV-delivered shRNA for knockdown of disease-driving genes (SNCA, HTT, SOD1)
- CRISPR components — AAV-mediated base editing or prime editing for precise genetic correction
- Systemic delivery — IV administration with engineered capsids at 1×10^14 vg/kg
- Intrathecal delivery — For direct CNS delivery with lower systemic exposure
- Combination approaches — Initial systemic dose followed by targeted intrathecal boosters
- AAV capsid engineering is established but combining with neurodegeneration-specific targeting is novel
- New machine learning approaches enable rapid capsid optimization
- Strong biological basis: receptor-mediated transcytosis is well-characterized
- Direct evolution has identified capsids with 10-100x enhanced brain transduction
- Addresses delivery bottleneck, not disease mechanism itself
- Can be combined with any genetic or RNA-targeting payload
- Manufacturing processes established for AAV at scale
- Clinical-grade capsid engineering feasible
- Lower dosing reduces immunogenicity risk
- Cell-type specificity improves safety profile
- Platform technology compatible with all gene therapy payloads
- Synergistic with RNA-targeting, CRISPR, and small molecule approaches
- Vector genome copy number in CSF as pharmacodynamic marker
- Reporter gene expression in patient-derived cells
- Clear path: capsid optimization in non-human primates → IND-enabling studies → clinical
- Regulatory precedent: AAV gene therapies approved for CNS (onasemnogene)
- Universal platform for AD, PD, ALS, FTD, HD, and other CNS diseases
- Addresses delivery across entire neurodegeneration pipeline
- Improved delivery could unlock gene therapy for previously inaccessible diseases
- Reduced dosing improves safety and access
Total Score: 82/100
| Disease |
Coverage Score |
Rationale |
| Alzheimer's Disease |
8 |
Astrocyte/microglial targeting for amyloid clearance |
| Parkinson's Disease |
9 |
Dopaminergic neuron targeting for SNCA, GBA |
| ALS/FTD |
9 |
Motor neuron and glial targeting |
| Frontotemporal Dementia |
8 |
Frontal cortex targeting |
| Huntington's Disease |
9 |
Striatal neuron targeting |
| PSP |
7 |
Brainstem targeting |
| MSA |
6 |
Mixed cell type targeting |
| Aging |
8 |
Platform applicable to age-related diseases |
- Screen existing engineered capsids (AAV-PHP.B, AAV-PHP.EB, CAP-NN) for neurodegeneration relevance
- Compare transduction in neurons, astrocytes, microglia from patient-derived iPSCs
- Select 2-3 lead capsids for IND-enabling studies
- GLP toxicology in non-human primates with lead capsids
- Develop scalable manufacturing process for engineered capsids
- Dose-finding study in relevant disease models
- Phase 1/2 trial in single disease (e.g., SOD1-ALS)
- Expand to additional indications with platform approach
- Pursue accelerated approval based on biomarker endpoints
- Immunogenicity — Engineered capsids may still generate immune response; mitigate with steroid pre-treatment and immunosuppression
- Manufacturing — Engineered capsids may have reduced packaging efficiency; optimize production in stable cell lines
- Specificity — May not achieve desired cell-type specificity; develop dual-targeting approaches
- Clear regulatory precedent with AAV gene therapies
- Breakthrough Therapy designation possible based on unmet need
- Accelerated approval pathway for life-threatening indications
- Literature review — Comprehensive analysis of 2024-2025 AAV capsid engineering literature
- In vitro screening — Test available engineered capsids in patient-derived neuron cultures
- Collaboration — Partner with AAV engineering groups (e.g., Univ. Pennsylvania, Cambridge)
- IND preparation — Pre-IND meeting with FDA for first neurodegeneration indication